"Breakthrough Study: Single Dose of MM120 Provides Lasting Relief from Anxiety"

A single dose of a new LSD formulation, MM120, has shown promising results in treating generalized anxiety disorder, leading to a 48% remission rate and significant improvement for 65% of patients within three months. The drug has received breakthrough therapy status from the FDA, and the biopharmaceutical company, Mind Medicine Inc., is developing it. The study's results also indicate potential benefits for depression symptoms. This marks the first time LSD has been studied in a medical setting in over 40 years, and the breakthrough designation will facilitate the drug's development process.